<DOC>
	<DOCNO>NCT02465450</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability , pharmacokinetics , efficacy JBT-101 adult subject cystic fibrosis ( CF ) .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics , Efficacy JBT-101 Cystic Fibrosis</brief_title>
	<detailed_description>An interventional , double-blind , randomize , placebo-control design use test safety , tolerability , pharmacokinetics , efficacy JBT-101 70 subject ≥ 18 &lt; 65 year age document cystic fibrosis . There screen period 28 day , 84 day treatment period , 28 day follow-up .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Documentation CF diagnosis evidence 1 clinical feature consistent CF phenotype 1 follow criterion : 1 . Sweat chloride equal great 60 mEq/L quantitative pilocarpine iontophoresis test ; 2 . Two wellcharacterized mutation CFTR gene FEV1 ≥ 40 % predict correct Stable treatment CF 14 day Visit 1 Severe unstable CF , : 1 . Intravenous antibiotic treatment within 14 day Visit 1 2 . Treatment corticosteroid &gt; 10 mg per day &gt; 20 mg every day oral prednisone equivalent within 14 day Visit 1 Any one follow value laboratory test Screening : 1 . A positive pregnancy test ( Visit 1 ) ; 2 . Hemoglobin &lt; 10 g/dL 3 . Neutrophils &lt; 1.0 x 10~9/L 4 . Platelets &lt; 75 x 10~9/L 5 . Creatinine clearance &lt; 50 ml/min accord modify CockcroftGault equation 6 . Serum transaminases &gt; 2.5 x upper normal limit 7 . Total bilirubin ≥ 1.5 x upper limit normal Any condition , opinion Principal Investigator , clinically significant may put subject great safety risk , influence response study product , interfere study assessment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>